Shareholders are Urged to Contact Wolf Haldenstein Adler Freeman & Herz LLP
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / WolfHaldenstein Adler Freeman & Herz LLP announces that it is investigating potential claims on behalf of purchasers of Eyenovia, Inc. ("Eyenovia" or the "Company") (EYEN). Shareholders who purchased stock in Eyenovia directly on the Company's January 2018 initial public offering ("IPO"), or in the aftermarket subsequent to the IPO, and have incurred losses, are encouraged contact the firm immediately at email@example.com or (800) 575-0735 or (212) 545-4774.
Eyenovia, Inc. operates as a biopharmaceutical company. The Company provides therapeutics for the treatment of eye diseases. Eyenovia discovers and develops ophthalmology products for glaucoma, mydriasis and dry eyes diseases. Eyenovia serves customers in the United States.
The Company's IPO was priced on January 25, 2018 at $10.00 per share and it is currently trading at $5.90 per share.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact WolfHaldenstein by telephone at (800) 575-0735, via e-mail at firstname.lastname@example.org, or visit our website at www.whafh.com.
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
SOURCE: Wolf Haldenstein Adler Freeman & Herz LLP